Churn in FDA’s inspection unit; Roche’s changing of the guard; Illumina on defense; NASH believer finds new challenge; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
We welcomed two new members to the editorial team last week: Jared Whitlock joined as features editor while Aayushi Pratap came on board as a news reporter. You might have read some of Aayushi’s news stories already, and Jared put out his first Endpoints In Focus piece this week, on Illumina’s conundrum. It’s an interesting read — check it out below.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.